Lenny Van Steenhuyse

@ohadhammer Blina isn’t exactly an optimized iteration of what we see in the field right now, plenty of room for improvement across target, safety, PK, depletion depth etc.

T cell engagers for I&I will have a lot of clinical readouts this year. This update (report from MS) from $AMGN on blinatumomab last week doesn't bode well for the class and it's unclear if next gen formats will have an advantage beyond dosing regimen. $CGEM will have an important clinical update in RA and SLE this Q.

@plainyogurt21 They did spend an obscene amount of money on them, I guess that's what it buys you.

godamn LLY using the co as in house dev team.

@NotGenentech @ohadhammer From a cleanliness perspective? Because it doesn't seem to internalize that well.

@ohadhammer CEACAM5 is a superior antigen.

Late line CRC therapies in development following $CTMX's data this week (from Guggenheim). A lot is riding on $CTMX's 10 mg/kg cohort which had just 19 evaluable patients (3 patients were excluded so ITT response rate is lower) so this needs to be corroborated in the dose optimization stage. Temab-A's ORR is probably in the 15-20% range in the broad CRC population (data in the table are for MET amplified CRC), making $CTMX's ORR superior for now.

The insistence on absurd and public flattery for the leader is a hallmark of authoritarianism. This kind of enforced sycophancy is not just ridiculous - it is dangerous. ft.com/content/4052d8… via @ft

@Andre_AGTC Could you elaborate on your $ 15 target? At that point valuation would land below cash, so you feel the current assets require way more cash still for derisking I guess.

$JANX (NP) Good science but need a lot of patience. Still too early regardless of analysts recomendations Still waiting JANX to hit my $15 target x.com/Andre_AGTC/sta…

LIFE’S CERTAINTIES: Roses are red Eric Tokat has a mission Centerview partners Acted as financial advisor to this acquisition

@semodough Practice-changing data, yet market doesn't care.

$KURA 93% (41/44) and 89% (24/27) CRcobserved in NPM1-m and KMT2A-r AML response-evaluable patients, respectively – – 71% (24/34) and 88% (14/16) CR measurable residual disease (MRD)-negativity observed among responding NPM1-m and KMT2A-r AML patients, respectively

@onco_park That is super interesting, thanks for sharing. I wonder what this means for EGFR x cMET bispecific ADCs in either mutational setting. Would induced proximity also influence the mechanism of internalization?

Is this $ARGX starting to be valued as a pharma company rather than a development biotech? Are investors now looking at EPS & PE multiples rather than pipeline promise? In any case, it's a momentous occasion to see them transition into profitability, what a behemoth of a company

@Prof_Oak_ Hard to hit that like button harder

Remarkable patient anecdotes - a wonderful scientific achievement $REGN Bummer that these programs faded into the obscurity of large pharma, where they will undoubtedly garner less coverage and visibility than if $DBTX and $AKUS were still standalone companies "A year after treatment in one ear with DB-OTO, a child born profoundly deaf was able to enjoy music, engage in imaginative play and participate in bedtime reading when the cochlear implant on their other ear was removed. These seemingly small interactions are life-changing for these children as well as their families"

Did the market expect $DYN to radically outperform $RNA? DM1 drug candidates look pretty similar and suddenly Dyne is heading into registrational cohort with 32 pts on 6M endpoint vs Avidity's 150 ph3 trial on 30w endpt. Time to market looks very close.

@ohadhammer And yet Otezla still doing > 2bn/yr. What happens when efficacy is cranked up drastically with manageable safety? IMO, these markets are so large that there will always be room for some uptake of orals, while perhaps not largest market share.

Great comparison from Morgan Stanley's analysts of new and next gen therapies for psoriasis. I think oral drugs (esp Tyk2 but also "oral biologics" like IL23 and IL17) will have a hard time competing with approved and half-life extended IL23 antibodies. Small molecules are unlikely to obtain the selectivity and safety profile seen with antibodies imo...

$LBPH fun fact on Longboard M&A: Lundbeck CEO Charl van Zyl was previously EVP neurology at UCB when they bought Zogenix for Fintepla, the very molecule bexicaserin is trying to improve on.

Presumably this is a mechanistic manifestation of long-term exposure, so 601 (next-gen Vox) likely done too Probably a win for orthogonal / polymerization-independent MOAs like $AGIO and $FULC, but will patients actually take them?

@JacobPlieth @A_May_MD Seems to me like a highly active drug with acceptable tolerability in a challenging setting. Also activity on C797S, while this isn't the case for firmo.

@A_May_MD Patients on therapy but no longer in response is weird. But still, these data seem pretty good. $BDTX <$300m $AVBP $800m+ ?

So $BDTX going in hard on PACC mutations in EGFR+ resistant NSCLC. Here's what $AVBP had to say about PACC at #WCLC24, via @ByMadeleineA oncologypipeline.com/apexonco/world…

@jq1234t @Sanctuary_Bio SG as an acquired asset can be considered ok, but I find that price quite difficult to wrap my head around. Challenging to see ROI on that for $GILD shareholders.

Pretty wild the divergence of fortunes in $GILD and $VRTX over the last decade Close to a decade ago Incivek was discontinued, and VRTX was forced to focus on their CF franchise Since then, VRTX has over quadrupled in stock price, GILD is down like 37%, lower mc than VRTX

@PDRennert Great overview

My blog post on these papers: sugarconebiotech.com/insights/recen…

While many people focus on the set of FRa ADCs with today's acquisition of ProfoundBio by $GMAB, I would argue raludotatug deruxtecan is another formidable competitor in the ovarian cancer field.

@BertrandBio @JacobPlieth The idea of bispecific ADCs continues to intrigue and could be really exciting. On the Hexabody tech, would imagine it likely that toxin conjugation would interfere with complement recruitment and internalization. If HexElect could be ADC-ified, that would be huge.

@JacobPlieth they really don't wanna show the linker, whereas it's already out with the INN description somehow... Also, $GMAB can make pretty funny ADC constructs if they want... not sure if all possible with any targets/payloads but they can do original things if they want

🇩🇰 $GMAB had signaled to be a buyer earlier this year, and has initial efforts in ADCs and I&I ongoing. Also hard for them to break through with bispecs in solids, so seeing them acquiring an #ADC co is all but surprising (was my bet, just the wrong co). Choice of lead ADC being

$GMAB swinging for the fences this morning. Great to see European big biotech dip its toes in meaningful M&A. $ 1.8bn sure is a significant ticket for a phase I/II FRa ADC, one of the most crowded targets around.